Spinal muscular atrophy (SMA) is characterized by the loss of amotoneurons (MNs) with concomitant muscle denervation. MN excitability and vulnerability to disease are particularly regulated by cholinergic synaptic afferents (C-boutons), in which Sigma-1 receptor (Sig1R) is concentrated. Alterations in Sig1R have been associated with MN degeneration. Here, we investigated whether a chronic treatment with the Sig1R agonist PRE-084 was able to exert beneficial effects on SMA. We used a model of intermediate SMA, the Smn 2B/À mouse, in which we performed a detailed characterization of the histopathological changes that occur throughout the disease. We report that Smn 2B/À mice exhibited qualitative differences in major alterations found in mouse models of severe SMA: Smn 2B/À animals showed more prominent MN degeneration, early motor axon alterations, marked changes in sensory neurons, and later MN deafferentation that correlated with conspicuous reactive gliosis and altered neuroinflammatory M1/M2 microglial balance. PRE-084 attenuated reactive gliosis, mitigated M1/M2 imbalance, and prevented MN deafferentation in Smn 2B/À mice. These effects were also observed in a severe SMA model, the SMND7 mouse. However, the prevention of gliosis and MN deafferentation promoted by PRE-084 were not accompanied by any improvements in clinical outcome or other major pathological changes found in SMA mice.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive, neuromuscular disorder predominantly characterized by a progressive loss of a-motoneurons (MNs), atrophy of skeletal muscles, and motor impairment (1) . With an incidence of 1 in 6000-10 000 live births and a carrier frequency of 1 in 35-50 (2, 3) , this disease is the leading genetic cause of infant mortality. SMA is caused by deletion or inactivating mutations of the survival motor neuron 1 (SMN1) gene located in the telomeric position of chromosome 5q13 (4) . SMN1 is ubiquitously expressed and plays a role in mRNA splicing by orchestrating small nuclear ribonuclear protein complex assembly (5) . Humans possess an almost identical copy of SMN1, referred to as SMN2, which is also located on chromosome 5, but in its centromeric region. SMN2 differs from SMN1 in terms of an exon 7 C-to-T transition. This change alters the normal splicing of mRNA and leads to the production of $85%-90% SMN2 transcripts that lack exon 7. When these transcripts are translated, a truncated and unstable protein (SMND7) is produced (6) , resulting in inefficient levels of functional, full-length SMN protein. Depending on the age of onset and the severity of disease, SMA can be clinically classified into several types, ranging from type I (the severest form) to type IV (the mildest form). The severity of the disease is inversely correlated with the SMN2 copy number (7, 8) . Thus, the most severely affected patients are usually the ones with the fewest copies of SMN2.
Because the identification of the loss-of-function defects in SMN1 gene as the cause of SMA, intensive efforts have been made to develop experimental therapeutic approaches to increase SMN protein (for reviews see [9] [10] [11] [12] ). Small molecules, such as antisense oligonucleotides, which promote SMN2 exon 7 inclusion and thereby increase full-length SMN2 transcription, and viral gene therapies, which directly replace SMN1, are promising strategies for SMA. In this regard, the antisense oligonucleotide Nusinersen, which acts as a splicing modifier targeting the intronic splicing silencer N1 in SMN2 intron 7 (13) , has been recently approved for SMA treatment. Clinical trials have shown that Nusinersen administration results in a significant improvement in motor function and survival of type I SMA infants (14) (15) (16) (17) . Even so, there is still a need for complementary, SMN-independent approaches that target cellular and molecular elements that are disturbed by the SMN deficiency. These therapies, used in synergy with SMN-targeted strategies, appear to be important for the long-term preservation of the neuromuscular structure and function (12) .
The reason why insufficient levels of SMN protein predominantly lead to MN loss is still unclear (18) . Moreover, it is known that not all MNs exhibit a similar susceptibility to degeneration in MN diseases: While some MNs degenerate early, others remain apparently undamaged until the endstages. This differential vulnerability of different MN subtypes appears to be related to their excitability (19) . The highly organized pattern of MN activity and excitability is modulated by cholinergic inputs delivered through C-type synaptic boutons. C-boutons may therefore be ultimately related to MN susceptibility to degeneration (20, 21) .
C-boutons exhibit a highly specialized postsynaptic organelle known as subsurface cistern, which is closely related to the endoplasmic reticulum (ER) and adjacent to the postsynaptic membrane (22) . The molecular organization of Cboutons includes M2 muscarinic receptors (23) , voltage-gated K þ channels (Kv2.1) and Ca 2þ -activated K þ channels (SK) (24, 25) , sigma-1 receptors (Sig1Rs) (26) , and neuregulin-1 (NRG-1) (27) . All of these molecules seem to be clustered in specific microdomains; however, the roles of some of them, including Sig1R and NRG-1, in C-bouton regulation are still unknown.
The Sig1R is a transmembrane protein with chaperonelike activity, which is widely distributed in mammalian nervous systems. This protein is particularly enriched in a subregion of the ER in which their cisternae come into contact with mitochondria (mitochondrion-associated ER membrane) (28) . Sig1R, which acts as an interorganelle signaling modulator, is involved in the regulation of ER-mitochondrion signaling and ER-nucleus crosstalk (29) . Sig1R also appears to play a role in unfolded protein response control and in the protection of cells from both oxidative and ER-mediated cellular stress (30) . Following ligand stimulation, Sig1R can also translocate from the mitochondrion-associated ER membrane to other parts of the cell. Sig1R can therefore interact with several different ion channels, receptors, and/or kinases in the plasma membrane (31) . In neurons, Sig1R mediates the regulation of several processes, such as neuritogenesis, K þ channel and N-methyl-Daspartate (NMDA) receptor activity, and Ca 2þ homeostasis (31) (32) (33) . Sig1R stimulation has also been shown to modulate multiple aspects of microglial activity (34) (35) (36) . Mutations of the Sig1R gene are related to MN disorders, such as amyotrophic lateral sclerosis (ALS) (37, 38) . Moreover, a lack of Sig1R exacerbates ALS progression in a mouse model of the disease (39) . The synthetic Sig1R agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE-084) has been reported to confer neuroprotection after excitotoxic stimuli in vitro (40) and after spinal root avulsion in rats (34) . Furthermore, the administration of PRE-084 in the SOD1 G93A mouse model extends survival and improves motor function by preventing MN death and preserving neuromuscular connections (41) . More recently, the neuroprotective effects of PRE-084 in a mouse model of MN disease not linked to SOD mutation have also been described (42) .
In the present study, we investigated whether chronic treatment with PRE-084 elicited beneficial effects on SMA. We used the Smn 2B/À mouse, a model for intermediate SMA (43, 44) , whose lifespan is prolonged until about 25-30 days and in which the phenotypic features of disease are more gradual than in murine models for severe SMA (e.g. Smn À/À ; SMN2 þ/þ or SMND7 mice). We started by examining the progression of pathological changes in the spinal cord, dorsal root ganglion, motor and sensory nerves, and neuromuscular junctions (NMJs) of Smn 2B/À mice throughout the disease. These changes were correlated with motor disabilities in mice. Here, we show that, in comparison with severe SMA murine models, the Smn 2B/À mouse exhibited substantial differences in the degree and time-course of MN degeneration and deafferentation. We also report that the PRE-084 treatment in Smn 2B/À robustly prevented reactive gliosis in the spinal cord and restored the altered microglial phenotypic (M1/M2) balance associated with SMA. Although PRE-084 partially prevented the loss of afferent inputs to MNs linked to SMA, it was, however, unable to prevent MN degeneration. PRE-084 was also able to improve neurofilament (NF) accumulation in motor nerve terminals, but failed to ameliorate other major pathological changes found at the NMJs in SMA mice. Furthermore, no improvement in survival or motor abilities was observed in SMA animals treated with PRE-084.
MATERIALS AND METHODS

Mice and Pharmacological Experiments With PRE-084
The SMND7 and Smn 2B/À mouse lines were used. To generate SMND7 animals, exhibit any apparent SMA phenotype (46) and were used as controls (hereafter referred to as WT). SMND7 mice exhibit a severe postnatal SMA phenotype, with overt symptomatology and pathological changes in the spinal cord and skeletal muscles at 7-8 days after birth, and have a mean lifespan of $2 weeks (47) (48) (49) (50) . Smn 2B/À animals develop a milder postnatal SMA phenotype, with a lower growth-related gain in body weight from about postnatal day (P) 12, and neuromuscular histopathological alterations and motor function deficits at about P16-17; Smn 2B/À animals have a mean lifespan of $3-4 weeks ( [46, 51] and our own observations).
At P0, a piece of tail was removed from the mice for genotyping. The REDExtract-N-Amp Tissue PCR Kit (Sigma, St. Louis, MO) was used for genomic DNA extraction and polymerase chain reaction setup. To distinguish between SMND7 mice and their WT littermates, the following primers were used: WT forward 5 0 ctccgggatattgggattg 3 0 , SMND7 reverse 5 0 ggtaacgccagggttttcc 3 0 , and WT reverse 5 0 tttcttctggctgtgccttt 3 0 . To identify Smn 2B/À mice, the gene that had to be detected was lacZ, which was used to interrupt the Smn murine gene (52) . The primers used were: lacZ forward 5 0 ttggcctgaactgccagctggcgcagg 3 0 and lacZ reverse 5 0 tcccgcagcgcagaccgttttcgctcg 3 0 . Electrophoresis in 1.5% agarose gel and SYBR safe DNA stain (Molecular Probes, Eugene, OR) was run at 100 V.
WT and SMA (SMND7 or Smn 2B/À ) mice were treated with either PRE-084 (Tocris Bioscience, Bristol, UK; 0.25 mg/kg/day) or the corresponding volume of physiological saline solution (vehicle). The PRE-084, or vehicle, was administered once a day, in the morning from P1 until the end of the experimental time frame, via subcutaneous interscapular injections. The dosage and regimen of PRE-084 administration used here were similar to those used in previous studies (41, 42) . At selected points in time, the mice were anesthetized with an intraperitoneal injection of pentobarbital (2%, 1 mL/ 10 g body weight), and transcardially perfused with physiological saline solution, followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) at pH 7.4. Mice used for electron microscopy studies were perfused with a solution containing 1% PFA and 1% glutaraldehyde in 0.1 M PB at pH 7.4. Tissue samples were rapidly dissected, removed, and subsequently processed as indicated below. All the experimental procedures were carried out according to the guidelines of the committee for Animal Care and Use of the University of Lleida, which have been approved by the Generalitat de Catalunya.
Behavioral Phenotype Testing
To evaluate disease progression, the mice were weighed every morning and carefully examined in order to detect the presence of any specific signs and/or symptoms of disease. Thereafter, the righting reflex and hind-limb suspension test ("tube test") were conducted to assess the motor abilities of the SMND7 mice from P0-1 until their death, and Smn 2B/À mice from P0-1 to P10. These tests were scored following the guidelines described previously (50, 53) .
From P10, the motor behavior of Smn 2B/À mice was assessed by performing a pen test and a grip test to analyze their motor balance and muscular strength. For the pen test, mice were placed on a suspended rope, as previously described (54) . The latency to fall and the number of hindlimbs that mice were capable of grasping on the rope (2, 1, or 0) were measured. For the grip test, mice were placed on a surface whose slope was progressively increased; we noted the maximum slope that the mice were able to remain on for a period of 20 seconds without falling (55) .
Tests were conducted by the same investigator (who was blind to the experimental condition). In each test, each individual mouse was examined 3 times, with a 15-minute recovery period between tests. The average values from the 3 independent tests were then determined in order to obtain the final score.
Muscle and Spinal Cord Histology and MN Counts
Tibialis anterior (TA) and intercostal (IC) muscles and spinal cords were rapidly dissected and removed for subsequent histological analysis and MN counting.
Muscles were weighed, postfixed in 4% PFA in 0.1 M PB (pH 7.4), cryoprotected with 30% sucrose in 0.1 M in PB, embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC), and frozen. Cryostat transverse sections (16 mm thick), obtained from the mid-belly of the muscle, were stained with hematoxylin and eosin (H&E).
For MN counts, spinal cords were fixed in Bouin's solution and embedded in paraffin. Serial transverse sections (14 mm thick), obtained throughout the entire lumbar segment, were stained with H&E. Apparently healthy MNs present in the ventral horn were identified by their size and shape and counted blindly on one side of every 10th section, following previously described procedures (56, 57) . Briefly stated, only MNs with a large nucleus, a visible clump of nuclear material, and a substantial cytoplasm were counted. The total number of MNs per ventral horn was obtained by multiplying the number of cells counted by 10.
Immunocytochemistry and Imaging
For immunocytochemical studies, TA and IC muscles, lumbar spinal cords, and L4 dorsal root ganglia (DRGs) were postfixed by immersion in 4% PFA in 0.1 M PB, at pH 7.4, either for 2 hours (in the case of muscles) or overnight (in the case of spinal cords and DRGs), and then cryoprotected. Tissue samples were embedded in tissue freezing medium and frozen. Longitudinal (for muscles, 16 mm thick) and transverse (for spinal cords and DRGs, 14 mm thick) serial cryostat sections were obtained and then stored at À80 C. Sections were sequentially rinsed for 30 minutes in phosphate-buffered saline containing 0.1% Triton X-100, then blocked in normal goat serum or normal horse serum, and subsequently incubated overnight with the chosen primary antibody. 
Image Analysis and Morphometry
Image analysis and morphometric examination were performed in a blinded manner by 2 independent investigators. The cytoarchitecture of the NMJs was analyzed in longitudinal immunostained sections of muscle. Z-stack optical sections (1 mm thick) were obtained and projected to reconstruct NMJs using microscope software. Five to nine sections were analyzed for each muscle and animal, and NMJs from randomly selected visual fields were evaluated for each experimental condition. NMJ size was assessed by determining the area of the a-Bgtx-labeled postsynaptic site, which was manually outlined using ImageJ software (National Institutes of Health, Bethesda, MD). An NMJ was considered to be denervated when the percentage of a-Bgtx-labeled postsynaptic surface covered by the SV2-stained presynaptic terminal was <15% (50, 58) . Based on the structural appearance of each postsynaptic site, the degree of NMJ maturity was classified as plaque, folds, perforations, or secondary structure (pretzel-like morphology), ranging from immature to mature, according to previously described criteria (50, 58) . NF was considered to accumulate in the presynaptic sites when the terminal portion of axons exhibited a swollen morphology and was strongly stained with the anti-NF antibody. Any NMJs that were difficult to analyze due to their location, orientation, and/or incomplete projection were excluded from the analysis.
Levels of GFAP and IBA1 immunoreactivity in the spinal cord were quantified by digital image analysis using ImageJ software. The number of NRG-1-and Sig1R-immunolabeled profiles and VAChT, VGluT1 and VGATimmunoreactive synaptic boutons on MN somata was counted on the screen; only boutons that were in close contact with MNs exhibiting a large nucleus, visible nucleolus, and healthy appearance were included in these counts; the numbers were then normalized to the perimeter of MN soma.
The number and soma area of CGRP, IB4, and PVimmunopositive sensory neurons in the DRGs were measured using digital images and ImageJ software. The area of DRG neurons was also assessed in sections counterstained with fluorescent Nissl stain.
Axon diameter and g-ratio measurements were performed on electron micrographs of VRs and DRs taken from mice at different points in time. For g-ratio analysis, we used the ImageJ g-ratio plug-in, which allowed us to obtain semiautomated measurements of randomly selected nerve fibers. The axon diameter was divided by the outer diameter of the myelin sheath. At least 100 myelinated axons per mouse (3 mice per condition) were measured. The number and diameter of healthy and degenerating myelinated axons were determined from 60Â images taken from VR and DR cross semithin sections stained with methylene blue. The images were joined together to obtain a whole picture of a complete nerve root transverse section. The diameter of the myelinated axons was measured by delineating the outer profile of the myelin sheath.
Western Blotting
Frozen spinal cords were homogenized with blending buffer 1 Â SR (2% SDS and 125 mM Tris-HCl, pH 6.8) supplemented with protease inhibitor (Sigma, Ref. P8340) and PhosSTOP (Roche, Laval, Canada). The samples were then heated to 100 C for 5 minutes and centrifuged at 13 500 g for 5 minutes. The protein concentrations were determined by BIO-RAD Micro DC protein assay (BIO-RAD, Laboratories, Inc., Hercules, CA). Loading buffer 4 Â SS (20% sucrose and 0.05% bromophenol blue, 0.1% sodium azide) containing 5%-10% b-mercaptoethanol (Sigma) and 15 mg of protein was then loaded into a 10% or 15% polyacrylamide electrophoresis gel. Proteins were electrotransferred to polyvinylidene difluoride (Immobilon-P, Millipore, Bedford, MA) membranes in a Tris-glycine-methanol-buffered solution. The membranes were then blocked with 5% dried skimmed milk in 0.1% Tween 20 and Tris-buffered saline pH 8 (TBST) for 1 hour at RT, and then washed in TBST. Immunodetection was performed by incubating the membranes overnight at 4 C with the following antibodies: rabbit polyclonal anti-NR1 (diluted 1:250; Abcam; no. ab17345); rabbit polyclonal anti-p-NR1 (Ser897, diluted 1:500; Millipore; no. ABN99); mouse monoclonal anti-SMN (diluted 1:1000; BD Biosciences, San Jose, CA; no. 610647); mouse monoclonal anti-b-actin (diluted 1:1000; Sigma; no. A54441). The antibody against b-actin was used for loading controls. The membranes were washed in TBST, incubated for 60 minutes at RT with the appropriate peroxidase-conjugated secondary antibodies (1:5000; Amersham Biosciences, Buckinghamshire, UK), washed in TBST, and visualized using the ECL Prime Western Blotting Detection Reagent detection kit (GE Healthcare, Buckinghamshire, UK), following the procedure described by the manufacturer. The quantification of band densities was performed by using Chemi-Doc MP Imaging System (BIO-RAD Laboratories, Inc.).
Statistical Analysis
Data were expressed as mean 6 standard error of the mean (SEM). The statistical analysis was assessed by either 1-or 2-way analysis of variance (ANOVA) followed by post-hoc Bonferroni multiple comparison test or 2-tailed Student t-test when only 2 different groups were compared. GraphPad Prism 6 software was used, and differences were considered to be statistically significant if p 0.05.
RESULTS
Behavioral Alterations, MN Loss, and Motor Axon Degeneration in Smn 2B/À Mice
With the progression of disease, SMA mice exhibit less body-weight gain than their WT littermates and suffer gradual impairment of their motor performance, as reported for different types of murine models (48) . Smn 2B/À mice develop a milder form of the disease, with phenotypic changes and motor deficits occurring more gradually than in other extensively used SMA mouse models (51) . In line with previous reports (59) , in Smn 2B/À animals, we did not find any significant reduction in body weight or any apparent alterations in motor abilities until P12-14, with a mean lifespan of $28 days (not shown). The changes in motor performance in Smn 2B/À mice observed in our study during the progression of disease are shown in Supplementary Data Figure S1A -E.
We first characterized the time of onset and the degree of MN death during the course of disease in the Smn 2B/À mice. Apparently healthy MNs were counted on H&E-stained transverse serial sections of the entire paraffin-embedded spinal cord lumbar segment, according to established criteria (56, 57) . In contrast to the moderate MN loss found in the lumbar spinal cord of different mouse models of severe SMA (i.e. Smn þ/À ; SMN2 þ/þ or SMND7 mice [49, 60] ), Smn 2B/À animals undergo progressive and prominent MN degeneration (Supplementary Data Fig. S2A ). In this model, a depletion of MNs had already been observed at P5, but was even more marked and significant at P10 ($30% of WT mice). Interestingly, and as mentioned above, at none of these ages did we detect any perceptible alterations in motor behavior in diseased animals. A still more dramatic fall in the number of MNs was seen at P20 ($75% of WT animals), followed by only a minor additional MN loss during the end-stage of disease (from P20 to P25-30). Smn 2B/À MNs also displayed a significant size reduction, which had already been noticeable at P5; this became particularly marked at P10 ($55% of WT MNs), but then barely changed from P10 to P25-30 (Supplementary Data Fig. S2B ). The appearance of MNs in the lumbar spinal cord of WT and Smn 2B/À mice is shown in Supplementary Data Figure S2C -G. In diseased animals, the scarce MNs that remained in the ventral horn at end-stages displayed an abnormal morphology compatible with ongoing cell degeneration. Some of these degenerating MNs appeared surrounded by nuclear profiles which probably corresponded to microglia recruited by the sick cell (Supplementary Data Fig. S2G ).
Several studies have reported the differential vulnerability of spinal MNs to degeneration in ALS (61, 62) . MNs innervating slow-twitch muscles (slow MNs) are therefore more resistant than those innervating fast-twitch muscles (fast MNs). In particular, fast-fatigable MNs are the ones most severely affected and which degenerate earliest during disease; they are followed by fast-fatigue resistant and slow MNs, which persist until later stages of disease. To determine whether the vulnerability of fast MNs is also a feature of SMA, we performed an immunocytochemical analysis of MMP-9 expression in the lumbar spinal cord of WT and Smn 2B/À mice. MMP-9 has been shown to be selectively expressed in fast MNs prior to the onset of ALS disease in SOD1 mice (63) . We did not find any signs of MMP-9 immunoreactivity in the spinal MNs of either WT or diseased animals at P1. However, as shown in Supplementary Data Figure  S2H and I-N 0 , at P5 $58% of WT MNs exhibited MMP-9-positive immunolabeling, whereas this was observed in $40% of the surviving Smn 2B/À MNs ($18% reduction vs WT, p < 0.05). The percentage of MNs showing MMP-9 expression then fell to $17% in Smn 2B/À mice at P20 ($48% reduction vs P20 WT, p < 0.001). Taking into account the fact that Smn 2B/À mice showed $16% fewer MNs than age-matched WT littermates at P5, overall these results suggest a preferential loss of fast-fatigable MNs during the early stages (P5) of disease in the Smn 2B/À mice; the degeneration of this MN subtype progresses until end-stages of SMA.
It has been hypothesized that MN death in SMA is a consequence of a retrograde "dying-back" degeneration of motor axons that occurs at postnatal ages (64) . This would imply that pathological changes would start in the distal part of the motor axons and/or NMJs, and progress to MN cell bodies. To explore whether or not axonal alterations preceded MN death, L4 VRs taken from WT and Smn 2B/À mice at different ages were embedded in plastic resin and then transversal sections were examined. As shown in Supplementary Data Figure  S3A , the VRs from WT animals exhibited a progressive increase in myelinated axon diameter (including the myelin sheath) during the whole postnatal period; this reflected the maturation process of the motor nerves. In contrast, in the VRs of Smn 2B/À mice, this normal axonal growth was significantly reduced at P25-30 (Supplementary Data Fig. S3A, B) . At all the time points studied, VRs from diseased mice contained fewer healthy myelinated axons than those from WT littermates (not shown). Moreover, a significant increase in the number of degenerating axons was observed in the VRs of Smn 2B/À mice from P20 onwards (Supplementary Data Fig.  S3C-K) . Interestingly, we noticed that at P5 $5% of the myelinated axons in Smn 2B/À VRs exhibited spheroidal masses resembling myelin ball structures, which were hardly ever seen in WT VRs (Supplementary Data Fig. S3L, M) . The ultrastructural analysis of VRs at P5 revealed that the vast majority of axons in WT animals exhibited a normal appearance (Supplementary Data Fig. S4A, B) . We only occasionally found some axons in WT VRs that showed structural regressive abnormalities (Supplementary Data Fig. S4B) ; this was probably the result of a physiological remodeling process taking place in the motor nervous system during the early postnatal period of development (65) (66) (67) (68) . Conversely, a significant number of motor axons in Smn 2B/À animals exhibited inclusions in the form of myelin-like multilaminar structures similar to those observed during Wallerian degeneration; in some cases, such myelin debris had been engulfed by phagocytic cells (Supplementary Data Fig. S4C-F) . Additionally, the axon diameter, determined by delineating the axon periphery under the myelin sheath, was found to be significantly longer in the VRs of Smn 2B/À mice than in those of their WT littermates; this would seem to indicate the presence of motor axon swelling in SMA (Supplementary Data Fig. S4G) . Conversely, the myelin in motor axons of diseased animals was significantly thinner (gratio: 0.69 6 0.01, n ¼ 100-125 per animal) than that in motor axons of WT mice (g-ratio: 0.63 6 0.01, n ¼ 100-123 per animal) (Supplementary Data Fig. S4H) . Supplementary Data Figure S4I shows a scatter plot displaying g-ratios as a function of axon diameter: All of the axons in VRs from diseased animals showing larger size corresponded to those with higher g-ratios (implying thinner myelin). On the other hand, the Schwann cells enwrapping axons in healthy animals appeared to be more mature than those observed around degenerating axons in Smn 2B/À mice (Supplementary Data Fig. S4A, D-F) . Overall, these data point to the expected existence of progressive atrophy and degeneration of motor axons as SMA progresses. Although in SMA animals this motor axon degeneration is not statistically significant until P20 (coinciding with both prominent MN loss and marked motor disabilities), axonal morphological alterations are already present at P5; these alterations include swelling, hypomyelination, and Wallerian-like degeneration and correlate with the incipient MN death found at the same time point of disease.
Changes in DRG Cells and DR Axons in Smn 2B/À
Mice
Sensory defects have been reported to occur in humans in the most severe forms of SMA (type I), but not in type II or III SMA (69) (70) (71) . It has been shown that DRG sensory neurons are also affected in Smn À/À ; SMN2 þ/þ mice, which are a model for human type I SMA (72) . To explore whether DRG neurons of Smn 2B/À mice also displayed pathological changes, L4 DRGs from WT and SMA mice were taken at P20, an age at which, as previously mentioned, we had observed massive MN degeneration. DRG sections were processed for immunocytochemistry using antibodies against CGRP and PV and stained with IB4 as specific markers for different neuronal subpopulations: CGRP is present in peptidergic sensory nociceptive neurons, which are small and unmyelinated; IB4 exclusively stains nonpeptidergic sensory nociceptive neurons, which are small and unmyelinated; and PV is localized in large sensory proprioceptive neurons that innervate muscle spindles (73) (74) (75) Data Fig. S5I ). These data indicate a marked loss of proprioceptive neurons and atrophy of nociceptive subpopulations in the DRG linked to SMA.
We next examined whether alterations in Smn 2B/À DRG neurons were accompanied by sensory axon defects. L4 DRs, obtained from WT and Smn 2B/À mice at different time points, were embedded in plastic resin and transversely sectioned. During the early stages of disease (P5 and P10) no phenotypic changes were seen in the sensory axons of Smn 2B/À . However, from P20 onwards, we noted a significant reduction in the DR area in SMA animals (Supplementary Data Fig. S6A-C) . The number of axons in the DRs was then counted at the end-stage of disease (P25-30). Although moderate axonal loss was found in Smn 2B/À DRs, this change did not reach a statistically significant level (Supplementary Data Fig. S6D ). Conversely, compared to WT littermates, Smn 2B/À mice exhibited a significant decline in the diameter of sensory axons (Supplementary Data Fig. S6E-H) . The absence of noticeable sensory axon loss in Smn 2B/À animals could be due to the fact that PVpositive proprioceptive neurons, which we found in smaller numbers in SMA, represent only a small proportion ($13%) of the total number of L4 DRG neurons (76) . On the other hand, the reduction in size of the sensory axons observed in SMA mice could result from the cell atrophy observed in other subpopulations of DRG neurons (e.g. CGRP-and IB4-positive neurons).
Reactive Gliosis in the Spinal Cord and MN Deafferentation in Smn 2B/À Mice
Astroglial and microglial reactions in the ventral horn of spinal cord are changes linked to SMA in humans (38, (77) (78) (79) (80) and severe murine models, including SMND7 (49, 50, 60, 80, 81) . To study whether glial activation also occurs in the spinal cord of Smn 2B/À mice, we analyzed astroglia and microglia after immunolabeling for GFAP and IBA-1, respectively. Diseased animals showed a progressive astrocytic reaction and prominent microgliosis around MNs. In relation to the ventral horns of WT animals, those of Smn 2B/À mice at P20 showed an increase in GFAP-positive profiles, which peaked at P25-30; spinal cords of Smn 2B/À animals also exhibited a significantly higher density of IBA1-positive microglia at P20, with only a slight reduction at P25-30 (Supplementary Data Fig.  S7A-H) .
SMA progression is accompanied by functional and structural alterations in the sensory-motor connectivity, resulting in MN hyperexcitability (27, 49, (82) (83) (84) (85) . We therefore sought to analyze any changes in afferent synapses on the MNs of the Smn 2B/À mice. To do this, the density of synaptic boutons on the MN somata was quantified in the lumbar spinal cord of WT and diseased animals at different time points. Glutamatergic excitatory and GABAergic inhibitory synapses were identified using antibodies against VGluT1 and VGAT. We found a gradual reduction in the density of both types of synapses as disease progressed. Compared to age-matched WT animals, the number of VGluT1 synapses on the MNs of Smn 2B/À mice was significantly reduced at P20 and, more prominently, at P25-30 (Supplementary Data Fig. S7I-O) . The density of VGAT-positive synapses on Smn 2B/À MNs was seen moderately, although significantly increased at P10. After this age, the VGAT-afferent density on Smn 2B/À MNs progressively declined, and therefore at P25-30 it was markedly lower than on WT MNs (Supplementary Data Fig. S7P-V) . The dramatic loss of VGAT-immunoreactive boutons at the end-stages in Smn 2B/À mice contrasts with previous findings in the SMND7 model, in which no reduction in the number of inhibitory inputs on MNs has been found at the latesymptomatic stages (49, 82) .
The potential changes in cholinergic inputs (C-bouton synapses) to MNs in SMA have been less explored (86) . Cboutons were immunolabeled using an anti-VAChT antibody. WT mice were found to display a progressive postnatal increase in the number of C-boutons on MNs (Fig. 1A) . Whereas MNs of both Smn 2B/À and WT mice exhibited similar densities of C-boutons from P5 to P20, a dramatic loss of this type of synapse was observed in Smn 2B/À MNs at P25-30 (Fig. 1A) ; indeed, at this age, MNs of diseased animals appeared to be almost devoid of cholinergic inputs (Fig. 1B-I ). This C-bouton depletion in Smn 2B/À MNs was not, however, accompanied by any change in their synaptic size (C-bouton area at P25
We next analyzed the expression of NRG1 and Sig1R, 2 proteins associated with C-boutons (27, 39, 87, 88) in WT and Smn 2B/À MNs. We had previously reported that NRG1 expression in spinal cord MNs dramatically decreased during the end-stages of disease in the SOD1 G93A mouse model of ALS, but not in SMND7 mice (27) . On the other hand, reduced levels of Sig1R in lumbar MNs had been found in SOD1 G93A mice, even during early pre-symptomatic stages (89) . We used specific antibodies against either NRG1 or Sig1R in combination with VAChT immunostaining to detect C-boutons. The percentage of C-boutons showing positive NRG1 was similar for both WT and Smn 2B/À MNs at P10 and P20, but was found to significantly fall in Smn 2B/À MNs at P25-30 (Fig. 1J, L, M) . On the other hand, the expression of Sig1R in C-boutons declined in Smn 2B/À MNs at P20, and this reduction was maintained at P25-30 (Fig. 1K, O, P) . It should be noted that in both WT and Smn 2B/À P10 mice, Sig1R immunoreactivity was extensively detected in the cytoplasm of MN somata, probably reflecting a high density of ER membranes (Fig. 1Q) ; even so, only a low percentage of C-boutons contained Sig1R at this age (WT: $8%, Smn 2B/À : $9%; p > 0.05, Student t-test, n ¼ 110-170 synapses; 3-4 mice per condition). At P20, however, the vast majority of WT MNs failed to show any signs of broadly cytoplasmic Sig1R immunostaining; conversely, Sig1R-positive profiles were seen postsynaptically associated with VAChT-positive C-boutons. These observations are consistent with previous reports showing that C-bouton-associated Sig1R expression only arises after the second week of postnatal development (88, 90) . Nevertheless, the reduction in cytoplasmic Sig1R normally observed at P20 did not occur in most of the MNs of Smn 2B/À mice (Fig. 1R) , apparently pointing to a defective Sig1R maturation process in SMA. A comparable developmental pattern of Sig1R was observed in MNs of SMND7 mice (not shown). Overall, these results demonstrate that, although some cholinergic terminals are still present at later stages of SMA, they do display defects in their postsynaptic molecular organization, such as the reduction in NRG1 and Sig1R expression.
Changes in the NMJs of Smn 2B/À Mice
As previously reported, the NMJs of SMA mice exhibit signs of denervation, NF accumulation, and morphological alterations that suggest a delayed synaptic maturation (50, 58, 60, (91) (92) (93) (94) . In severe mouse models of SMA, these alterations appear to be more prominent in certain muscles in the head and trunk than in those distally located in limbs, which frequently remain fully innervated until later stages of disease (50, 82, 94) . To examine whether the NMJs of proximal and distal muscles of Smn 2B/À mice also display differential vulnerability, the proportions of NMJ denervation and NF accumulation were examined in IC and TA muscles of WT and Smn 2B/À mice from P10 to P25-30. To do this, muscles were immunolabeled with antibodies against NF and SV2 to recognize the presynaptic compartment, and then stained with a-Bgtx to identify the postsynaptic site. In relation to WT mice, Smn 2B/À animals showed a higher percentage of NMJ denervation and NF accumulation in both IC and TA muscles; however, the NMJs of IC muscles appeared to be more severely denervated and exhibited abnormal NF aggregation at an earlier stage than those in TA muscles (Supplementary Data Fig. S8A-D, I-P) . In the IC muscles of diseased animals, a significant degree of denervation and NF accumulation was already evident at P10 and even more prominent at P20; in contrast, in the TA muscles of Smn 2B/À mice, the number of NMJs exhibiting NF accumulation was not significant until P20, and then dramatically increased at P25-30-the age at which significant denervation was also noticed. Interestingly, at P25-30 a reduction in the percentage of denervated NMJs was observed in IC muscles of Smn 2B/À animals ( Supplementary Data Fig. S8A ), suggesting that compensatory mechanisms of denervation could exist throughout the course of the disease. In fact, increased levels of axonal sprouting have been observed in the NMJs of different SMA mouse models (50, 60, 91, 95) , including those in Smn 2B/À mice ( [96] and our own observations). The architectural analysis of postsynaptic sites also revealed that NMJs of both IC and TA muscles were smaller and less mature in Smn 2B/À mice than in WT littermates, with a significant increase in the number of NMJs exhibiting a plaque and fold structure and a dramatic reduction in the number of those showing a perforated or pretzel-like (second structure) morphology (Supplementary Data Fig. S8E-H) . Overall, these changes also occurred at an earlier stage and were more prominent in IC than in TA muscles. These data, when compared with those reported in SMND7 mice (50, 82, (92) (93) (94) in which hindlimb muscles remained innervated throughout disease progression, suggest that the slower the SMA progression is (as in the Smn 2B/À mouse model) the greater is the degree of impairment in the NMJs of the distal (e.g. TA) muscles at end-stages.
Chronic Treatment With PRE-084 Did Not Improve Lifespan or Motor Abilities in SMA Mice
We next wanted to establish whether the clinical SMA phenotype could be attenuated by the chronic administration of the Sig1R agonist PRE-084. SMND7 and Smn 2B/À mice, and their respective WT littermates, were treated daily with either PRE-084 (0.25 mg/kg) or saline from P1 onwards. Body weight and survival were measured and a battery of tests was performed to evaluate motor function. As expected, SMND7 and Smn 2B/À mice treated with saline showed a lower growthrelated gain in body weight than saline-injected WT animals. PRE-084 administration did not have any apparent influence on body weight in either of these models or phenotypes ( Supplementary Data Fig. S9A; Fig. 2A ). The righting reflex and tube test were used to assess muscle strength and motor coordination in SMND7 mice throughout their lifetime, and in Smn 2B/À animals from P1 to P10. Both saline-and PRE-084-treated SMND7 mice required similar times to right themselves on all 4 paws, demonstrating significant difficulties in righting themselves in comparison with saline-and PRE-084-treated WT mice (Supplementary Data Fig. S9B) . Similarly, SMND7 animals, independently of their treatment (either with saline or PRE-084), had shorter latencies to fall and registered worse scores compared to their age-matched WT mice when they were assessed using the tube test (Supplementary Data Fig. S9C ). As expected, no differences were observed between Smn 2B/À animals and their WT littermates when the righting reflex and tube tests were performed from P1 to P10 (data not shown). From P10 onwards, the pen test and the grip test were applied to assess motor abilities in the Smn 2B/À model. Compared to WT mice, at P10, the diseased animals presented significantly shorter latencies to fall and lower scores in the pen test; these differences were maintained during the rest of the period studied. Similarly, from P16 on, the Smn 2B/À animals showed worse performances in the grip test than the WT mice. PRE-084 administration did not produce any significant change in motor abilities of either WT or diseased mice. (Fig. 2B, C) .
The Sig1R-agonist treatment was unable to prolong the lifespan of SMND7 or Smn 2B/À mice: Saline-and PRE-084-treated diseased animals showed similar KaplanMeier survival curves and mean survival rates (SMND7-saline: 14. 67 Fig. S9D; Fig. 2D ).
PRE-084 Administration Did Not Prevent MN Loss or Any Major Pathological Changes Found in the NMJs of Smn 2B/À Mice
We next explored whether PRE-084 treatment was able to prevent MN death in the Smn 2B/À mouse. We restricted these experiments to this model due to the fact that, as previously mentioned, despite being more prominent, spinal cord MN degeneration in these mice is slower than in SMND7 mice. Lumbar spinal cord MNs were counted in WT and diseased animals at P20. PRE-084 administration did not have any significant effect on MN numbers in Smn 2B/À mice (Fig. 3A) . G93A mice (41) . As NMJ alterations were more gradual and less severe in the TA muscle, this was used to explore the effect of PRE-084 on neuromuscular histopathology in Smn 2B/À mice. No significant structural changes in NMJs of PRE-084-treated WT animals were observed in comparison with saline-injected WT mice (not shown). Chronic PRE-084 administration mitigated the aberrant NF accumulation in nerve terminals (Fig. 3B, J, N) , but it did not prevent muscle denervation in diseased animals (Fig. 3C) . PRE-084 treatment improved neither the degree of atrophy nor the immaturity of Smn 2B/À NMJs ( Fig. 3D-Q) . The existence of muscle denervation despite the reduction in NF accumulation in the nerve terminals of PRE-084-treated SMA mice is in agreement with previous findings, which suggest that NF aggregation does not correlate with NMJ vulnerability and does not predict subsequent muscle denervation (94) .
PRE-084 Treatment Mitigated Reactive Gliosis and Restored the Imbalance of Microglial Phenotypes Associated With SMA
Following chronic PRE-084 treatment, significant reductions in reactive astrogliosis and microgliosis were noted in both SMND7 and Smn 2B/À mouse models (Fig. 4A-J) . When activated in neuroinflammation, microglial cells can develop to 1 of 2 opposing maturation states: M1 and M2 phenotypes (97) (98) (99) . The M1 phenotype has been associated with degeneration and inflammation, while the M2 phenotype has been related to regenerative and anti-inflammatory processes. In neurodegenerative diseases, microglial cells may play either a harmful (M1 phenotype, "classical activation") or Values are shown as mean 6 SEM, n ¼ 10-12 mice per condition; no significant differences in body weight, or pen and grip test performance were observed between saline-and PRE-084-treated Smn 2B/À animals (2-way ANOVA, Bonferroni post-hoc test). (D) Kaplan-Meier survival curve for the different experimental groups. Saline-and PRE-084-injected Smn 2B/À mice do not show any significant differences in mean survival (22.11 6 0.87 and 21.00 6 0.79 days, respectively; p > 0.05, Student t-test, n ¼ 12 animals per condition). As no significant differences were observed between saline-and PRE-084-treated WT mice in any of the tests used to assess motor behavior, data from the PRE-084 WT group were excluded to simplify the graphs. beneficial (M2 phenotype, "alternative activation") role; this depends on their intrinsic properties, the milieu in which they are activated, and the factors that they are stimulated by (98, 99) . We therefore next examined whether the inhibition of microgliosis by PRE-084 implied the induction of the M2 phenotype. IBA1 immunohistochemistry was combined with Mac-2 or CD206 immunolabeling for M1 and M2 microglia, respectively (100-102). Compared to WT animals, Smn 2B/À mice were found to exhibit a dramatic increase in harmful M1 (Mac-2-positive) microglia and a significant reduction in beneficial M2 (CD206-positive) cells in the spinal cord. PRE-084 treatment reduced the density of the Mac-2-immunoreactive profiles and enhanced the number of CD206-immunolabeled cells found in Smn 2B/À spinal cord (Fig. 4K-R 00 ). These results indicated that the pharmacological activation of Sig1R prevents the M1/M2 imbalance associated with SMA.
PRE-084 Reversed the Loss of Synaptic Afferents to MNs in Smn 2B/À Mice
It had been previously shown that, in pathological conditions, activated microglial cells physically interact with damaged neurons and are able to remove synaptic afferents (reviewed in [103] ). As PRE-084 prevents reactive gliosis in the spinal cord of SMA animals, we explored whether this agent was also able to attenuate glial-dependent MN deafferentation. Spinal cord sections immunolabeled for VAChT, VGluT1, or VGAT were examined in order to quantify the number of positive puncta on the MN somata of P20 WT and Smn 2B/À animals treated with either saline or the Sig1R agonist. PRE-084 did not significantly change the density of VAChT-immunolabeled synapses compared to MNs of salinetreated Smn 2B/À animals ( Fig. 5A-D  0 ) . However, PRE-084-treated Smn 2B/À mice showed a significant rescue of VGluT1-positive boutons (Fig. 5E-H 0 ) and prevented the moderate loss of VGAT synapses (Fig. 5I-L 0 ) resulting from disease.
PRE-084 Treatment Did Not Modify Sig1R or NRG1 Expression in the Spinal Cord of Smn 2B/À Mice
Previous studies had reported that Sig1R agonists were able to promote their action by means of Sig1R upregulation via a positive-feedback mechanism (104). We therefore decided to examine whether chronic PRE-084 treatment modulates the expression of Sig1R in Smn 2B/À mice ( Fig. 6A-O) . Western blot analysis, used to determine Sig1R levels in the spinal cord, revealed no significant differences in the amount of this protein between the different experimental groups (Fig. 6A, B) . To assess whether PRE-084 affected Sig1R expression in MNs, we performed a double immunofluorescence with antibodies against Sig1R and VAChT (for C-bouton identification) on spinal cord sections from WT and Smn 2B/À mice. PRE-084 did not modify the reduced numbers of C-boutons associated with Sig1R-positive profiles found in MNs of diseased animals (Fig. 6C-O) . NRG1-positive profiles were also quantified in sections that were co-immunostained with anti-NRG1 and anti-VAChT antibodies. MNs of PRE-084-and saline-treated Smn 2B/À mice exhibited similar numbers of C-boutons expressing NRG1 (percentage of VAChTpositive boutons associated with NRG1-positive profiles: 
Mice
Western blot analysis was used to determine whether the beneficial effects of PRE-084 on reactive gliosis and MN deafferentation seen in SMA were a consequence of an increase in the expression levels of SMN in the spinal cord. Similar low levels of SMN were found in extracts from diseased mice treated with either saline or PRE-084 (Fig. 6P, Q) . A previous in vitro study using rat ganglion cells had shown that PRE-084 modulated NMDA receptors (105) . It had also been previously reported that the therapeutic effects of PRE-084 on SOD1 G93A mice were mediated by the phosphorylation of the NMDA receptor subunit NR1 at serine-896 and serine-897 (41) . Using antibodies against NR1 and p-NR1 (Ser897), we performed Western blots of spinal cord extracts from WT and Smn 2B/À animals treated with either saline or PRE-084. No changes were observed in either total NR1 or p-NR1 protein levels when we compared samples from Smn 2B/À mice treated with saline and PRE-084 (Fig. 6R-T) .
DISCUSSION
In the present study, we used the Smn 2B/À intermediate mouse model of SMA (43, 44) to provide a detailed characterization of the progression of the histopathological phenotype throughout the disease course, including: MN degeneration, defects in the DRG, changes in spinal cord central synapses, glial reaction, and alterations in NMJs. The correlations of these changes with functional motor deficits were also examined. As C-bouton alteration and reactive gliosis were found to be prominent features in Smn 2B/À mice, we explored the Cerver Representative confocal micrographs used for data analysis shown in (K) and (L); cryostat sections of lumbar spinal cord from WT and Smn 2B/À mice, treated with either saline or PRE-084, were processed for immunocytochemistry with antibodies against IBA1 (green) and either Mac-2 or CD206 (red); arrows in (P 0 ), (Q 0 ) and (R 0 ) indicate CD206-positive cells located in the periphery of the spinal cord white matter, as previously reported (42); note that the number of these cells decreases in sections of Smn 2B/À mice; this change is restored after PRE-084 treatment. Dotted and dashed lines in pictures delimitate the boundaries of gray matter and white matter (spinal cord section periphery), respectively. The data in the graphs are expressed as mean 6 SEM; n ¼ 4 animals per condition in each genotype; *p < 0.05, **p < 0.01 and ***p < 0.001 (1-way ANOVA, Bonferroni post-hoc test). Scale bars ¼ 200 mm in G and J (valid for E and F, and H and I, respectively), and in R 00 (valid for M-R 00 ).
potential therapeutic effects of the Sig1R agonist PRE-084 in this model. The findings were then extrapolated to the SMND7 mouse, a widely used severe model for the disease.
Here we report that Smn 2B/À mice suffer gradual and prominent MN degeneration in the lumbar spinal cord (>75% of the MNs present in WT animals died), starting during the early-presymptomatic stages of SMA; this contrasts with the þ/þ and SMND7 mice) of the disease (49, 60) . We also show that fast MNs are more vulnerable to degeneration in SMA than slow ones. Additionally, we demonstrate structural alterations in motor axons that are already occurring during the early-presymptomatic stages of the disease. Motor axon defects coincide with the onset of MN death and occur in the absence of overt pathological changes in the NMJs of hindlimb muscles. We also report the existence of a dramatic loss of proprioceptive neurons and atrophy of both peptidergic and nonpeptidergic nociceptive neurons in the DRG of Smn 2B/À mice. Changes in DRG neurons are accompanied by structural defects in sensory axons and the loss of afferent inputs to MNs. We also show, confirming previous findings in the most severe models of SMA, that Smn 2B/À mice display a prominent reactive gliosis in the spinal cord, which includes a disruption of the M1/M2 microglia phenotype. Chronic PRE-084 treatment attenuates reactive gliosis and restores the altered M1/ M2 balance in SMA. This suggests a potential therapeutic effect of the Sig1R agonist by promoting M2 polarization and, in this way, favoring the beneficial anti-inflammatory action of microglia in SMA. This effect correlates with the prevention of the MN deafferentation process that takes place in the course of the disease. However, the beneficial effects of PRE-084 on gliosis and afferent inputs to MNs are not accompanied by either any improvement in lifespan or motor performance; PRE-084 similarly fails to prevent MN loss or to mitigate any of the major pathological changes present in the NMJs of SMA mice.
Remodeling and maturation processes occur in the central and peripheral nervous system during the first postnatal weeks (56, 106) . Sig1R is enriched in mouse spinal cord MNs, in which the protein is first visualized in the ER at later stages of embryonic development, and then concentrates in C-boutons during the second postnatal week (88, 90) . The Sig1R location in C-boutons (88, 107) suggests the involvement of this receptor in the modulation of cholinergic synapses and, as a consequence of this, also in MN excitability and susceptibility to degeneration (20, 21, 108) . We found changes in the normal distribution of Sig1R on MN somata and a defect in its association with C-boutons in SMA mice; for instance, whereas at P20 the vast majority of WT MNs exhibited Sig1R in C-boutons with only a minimal cytoplasmic expression of this protein, most of the Smn 2B/À MNs still displayed extensive cytoplasmic Sig1R immunoreactivity. These results were, at least in part, comparable to those described in the wobbler mouse, a model for spontaneous MN degeneration (42) . A link between Sig1R gene mutations and distinct neurodegenerative diseases has been reported (37, 38) . Moreover, it has been shown that Sig1R alterations may lead to MN dysfunction and degeneration (39, 109) . Reduced levels and an abnormal distribution of Sig1R protein in the spinal cord of patients and mouse models for ALS have also been noticed (41, 110) . In our work, we did not detect any altered levels of Sig1R protein in lumbar spinal cord extracts from Smn 2B/À mice; however, by immunocytochemistry, we observed a reduced expression of Sig1R at C-boutons in this SMA model at P20, coinciding with the full symptomatic stage. This reduction in the synaptic levels of Sig1R persisted until the terminal stages of the disease. Even so, we did not find any changes in the pattern of Sig1R expression in the presymptomatic stages (e.g. at P10). These findings cannot be generically applied to MN diseases because in ALS mice reduced Sig1R levels have been found both in the whole spinal cord and in C-boutons during the early presymptomatic stages (41). Although we cannot rule out a role for Sig1R in SMA pathogenesis, the fact that the defects in the motoneuronal expression of this protein did not occur until advanced stages would suggest a late involvement of Sig1R in the neuromuscular dysfunction linked to this disease. This would explain why in Smn 2B/À mice, MN loss ($16% of WT) had already been detected at P5, an age at which no significant differences in C-bouton density were found between WT and diseased animals. MN death continued as disease progressed, so at P10 a significant decrease (>30% of WT) in the number of apparently healthy MNs was seen in SMA mice, but no apparent changes were noted in either the density of C-boutons or the number of those displaying Sig1R-positive immunolabeling. Moreover, the significant reduction in Sig1R expression in C-boutons on Smn 2B/À MNs observed at P20 (when $ 65% MNs had already been lost) was not accompanied by changes in C-bouton density on the remaining MNs. Whereas in Smn 2B/À MNs, the reduction in Sig1R expression at C-boutons had already been detected by P20, the loss of VAChT-labeled C-bouton terminals was not seen until P25-30. This indicates a dissociation in the loss of pre-(VAChT) and post-synaptic molecules (Sig1R) at C-boutons. The reduction in Sig1R expression found in C-boutons of Smn 2B/À MNs is therefore an event that clearly precedes the loss of this type of synapse during the end-stages of the disease, when a large number of MNs had already died.
Given its close proximity to Kv2.1 and to SK channels in C-boutons, Sig1R appears to play a role in the modulation of postsynaptic excitability and, subsequently, MN vulnerability. In fact, in a number of different experimental models, it has been reported that Sig1R can regulate the activity of Kv and SK channels (111, 112) and that Kv2.1 and/or SK channel activation inhibits MN excitability (20, 21, 25, 113) . Conversely, increased excitability was found in MNs exhibiting a reduction in Sig1R expression (107) . On the other hand, Sig1R has also been involved in the regulation of Ca 2þ homeostasis by modulating Ca 2þ entry through plasma membrane (i.e. via voltage-dependent Ca 2þ channels), and Ca 2þ flow from ER and to mitochondria (i.e. via inositol triphosphate type 3 receptor) (28) . Sig1R also appears to modulate NMDA receptor activity (105) and, subsequently, Ca 2þ influx in neurons. In the present study, the activation of Sig1R by its agonist PRE-084 did not prevent MN degeneration or motor deterioration in Smn 2B/À mice. These results contrast with the neuroprotective action and improvement in motor performance conferred by PRE-084 in the SOD1 G93A (41) and wobbler (42) mouse models of MN disease. Taking into account the fact that these studies used similar dosages and regimens of PRE-084 administration to the ones we used in the present work, it is possible that differences in the rates of disease progression and in the pathogenic mechanisms could account for the disparities in the results. In fact, both disease models (SOD1 G93A and wobbler mice) have a slower clinical outcome with a longer lifespan and exhibited neuropathological alterations that start later and evolve more gradually than those in Smn 2B/À mice ( [46, 51, 114, 115] , and our own observations). On the other hand, it has also been reported that PRE-084 is able to protect MNs against excitotoxic insults (40) and to prevent MN degeneration in SOD1 G93A ALS mice (41) through the modulation of NMDA receptors via the protein kinase C pathway. In the latter work, the authors reported a significant increase in the phosphorylation of NMDA-NR1 subunits in spinal cord extracts and also in MNs of mice treated with PRE-084 (41). These findings suggest that the neuroprotective action of PRE-084 could be due to a subsequent reduction in the Ca 2þ permeability of NMDA receptors and, consequently, to a decrease in the influx of Ca 2þ into MNs. We did not, however, detect any significant change in NR1-subunit phosphorylation in spinal cord samples from PRE-084-treated Smn 2B/À mice. Although we cannot conclude that the absence of a modulatory action on NMDA receptors is responsible for the lack of neuroprotection found after PRE-084 administration in our system, it must be taken into account that the regulation of intracellular Ca 2þ homeostasis throughout NMDA-receptor modulation is considered a major mechanism through which Sig1R agonists promote neuroprotection (116, 117) .
Neuroinflammation, which involves the reactive activation of both microglia and astroglia, is a common process in a number of different neurodegenerative diseases, including ALS (118, 119) . Reactive gliosis has also been described in SMA, in both humans (78, 79) and severe mouse models of the disease (49, 82, 120) . However, the role of neuroinflammation in SMA pathogenesis has still to be properly elucidated. In fact, the glial reaction associated with neurodegenerative disorders may have either deleterious (cytotoxic) or beneficial (neuroprotective) effects on MNs ( [80, 99, 101 ] as reviews). Microglia are heterogeneous cells that exhibit different functional states that can be categorized in 2 opposing phenotypes: M1 (proinflammatory) and M2 (immunosuppressive and neuroprotective). M1 microglia can turn into M2 microglia, and vice versa, depending on the context in which they are activated. This dynamic transformation of M1/M2 phenotypes appears to play a critical role in neurodegeneration. In pathological conditions, neuronal death has therefore been related to a broken balance between the 2 microglial (M1/M2) subpopulations as a consequence of the sustained activation of M1 cells (99, 101) . Similarly, it has recently been reported that neuroinflammation can induce 2 different subtypes of reactive astrocytes: A1 and A2 (in analogy to the references used for M1 and M2 microglia) (121); whereas A2 astrocytes might be neuroprotective, A1 astrocytes appear to be detrimental and to develop neurotoxic functions following their activation by reactive microglia (121) . Here, we show that marked microglia and astroglia activation also occurs in the spinal cord of Smn 2B/À mice, in which phenotypic and pathological changes linked to SMA take place later and more gradually than in severe mouse models of the disease (48) . We also report that microgliosis in SMA is accompanied by a significant increase in M1 microglia at the expense of a reduction in M2 microglia. Moreover, and in agreement with what has been observed in severe SMA mouse models (i.e. SMND7 mice, [49] ), reactive gliosis in the spinal cord of Smn 2B/À animals starts several days after MN degeneration and coincides with the overt loss of glutamatergic excitatory synapses. On the other hand, the reduction in the density of inhibitory GABAergic and cholinergic synapses on Smn 2B/À MNs is only significant at the endstages of the disease, some days after the onset of marked and sustained gliosis around degenerating neurons. Overall, these results extend our previous findings regarding severe mouse models of SMA (49, 60) and support the assumption that microglial cells do not play an active role as inductors of MN degeneration in this disease. Accordingly, we have not observed any significant microgliosis in the spinal cord of Smn À/À ; SMN2 þ/þ mice (an SMA model which is more severe than SMND7) at the end-stages of the disease, coinciding with the maximal loss of MNs (60) . It is therefore more likely that microgliosis is a secondary reactive process resulting from MN dysfunction. In this regard, we found that motor axons of Smn 2B/À mice undergo overt histopathological changes at as early as P5, a time point at which MN loss, although present, is not yet significant and mice do not exhibit any apparent motor disabilities. Alterations in motor axons of P5 Smn 2B/À mice include swelling, hypomyelination, and Wallerian-like degeneration. These changes may reflect a primary distal alteration ("dying-back") or, alternatively, a secondary response to an earlier MN dysfunction. Whatever the case, altered MNs can create a pathological environment in the spinal cord which is critical for the activation of glial cells and promoting their physical interaction with damaged MNs (103) . It is known that, under pathological conditions, microglia play a role not only in removing damaged neurons but also in detaching and engulfing altered afferent synapses, in a process called "synaptic stripping" (122) . A similar task has also been described for astrocytes in actively eliminating dysfunctional synapses (123) . It has been proposed that synaptic stripping would lead to the disconnection and removal of defective afferent inputs to MNs; this would form part of an attempt to protect them and to leave space to be subsequently occupied by healthy synaptic inputs (124) . The time course of glial changes in SMA reported here would favor this role of removing synaptic inputs to MNs. It is well known that the progression of disease in SMA mouse models is associated with functional and structural changes in afferent synapses to MNs (27, 49, (82) (83) (84) (85) and that this leads to their progressive deafferentation. We, and others, have previously reported that in severe SMA mouse models (e.g. in SMND7 mice), the loss of afferent synapses (and particularly glutamatergic inputs) starts at prenatal ages and precedes MN death (49, 84) . Interestingly, we found here that MN deafferentation in Smn 2B/À mice occurs during the end-stages of the disease and correlates with degenerative changes in DRGs and sensory nerves in the DRs. We therefore observed a significant loss of proprioceptive neurons expressing PV and the atrophy of nociceptive CGRP and IB4-positive neuronal subpopulations in the DRGs of Smn 2B/À mice at P20. This corresponded with the point when their MNs exhibited a marked reduction in glutamatergic inputs but still retained their GABAergic and cholinergic afferents, which were not significantly reduced in number until P25-30. Importantly, despite the fact that MN death had already started by P5, no apparent structural signs of glutamatergic synapse loss were detected before P20. Although it has been reported that deafferentation does not contribute to MN death in SMA (113) , the role of central synapses in the pathogenesis of this disease still remains a subject of discussion (50, 58, 113, 125, 126) . In this regard, it has been shown that abnormal MN development due to SMN deficiency results in both MN dysfunction and afferent input defects which can be corrected by expressing SMN in MNs (127) . Since MN deafferentation in Smn 2B/À mice occurs during the end-stages of the disease, in agreement with Fletcher et al (113) , we must conclude that the loss of synaptic afferents is not necessarily linked to MN death. Nevertheless, we cannot exclude the existence of an altered function in remaining central synapses on SMA MNs. In fact, it has been shown that a dysregulation of different MN synaptogenesis genes, which are required for the correct functioning of sensory-motor circuitry, precedes MN pathology (128) . It is reasonable to consider that such changes in afferent input activity could have a negative impact on the integrity and function of MNs, thereby contributing to their progressive degeneration and favoring glial reaction in SMA. It has therefore been reported that, following axotomy, alterations in presynaptic activity would tend to precede MN deafferentation by microglia, a process which appears to play a critical role in MN survival after nerve injury (129) .
In the central nervous system, Sig1R is not only expressed in neurons but also in microglial cells (130) and astrocytes (131) . Sig1R stimulation in vitro has been found to modulate multiple aspects of microglial activity (including the morphological, migratory and inflammatory responses) (36, 132, 133) and also the inflammatory reaction to several known macrophage activators in the peripheral immune system (134) . Sig1R agonists have also been reported to attenuate astrogliosis in a rodent model for stroke injury (135) , and to regulate astrocytic activity (136) and the expression of neurotrophic factors following MN injury (34) . The mechanisms by which Sig1R ligands regulate glial activity are not well defined. It has been reported that, in astrocytes, Sig1Rs may modulate the JAK2/STAT3 signaling pathway (137) and, also, induce the activation of cAMP-response element-binding protein following previous activation of Src and ERK MAPKs cascade (104) . However, further investigations are necessary to delineate the molecular mechanisms involved in the regulation of glial activity by Sig1R agonists. Here, we show that PRE-084 was able to prevent reactive gliosis in both of the mouse models for SMA (SMND7 and Smn 2B/À mice) used in the study. We also found that PRE-084 restored the microglial phenotype (M1/M2) balance altered by the disease. This result is in agreement with the previously reported action of PRE-084 counteracting the M1/M2 imbalance in the wobbler mouse (42) . However, contrasting with this finding, the beneficial effect of PRE-084 on neuroinflammation in our model was not accompanied by the prevention of MN degeneration. Nevertheless, we noticed that the Sig1R agonist was able to mitigate the loss of the synaptic inputs that occur in MNs during SMA progression. Overall, these data suggest that the activation of glial Sig1Rs can inhibit the synaptic stripping process resulting from reactive gliosis and show that the prevention of MN deafferentation is not sufficient to inhibit neurodegeneration in SMA. It has been reported that deficient levels of SMN result in intrinsic changes in the functional properties of MNs, which show higher excitability than under normal conditions (85, 138) . Moreover, the restoration of SMN in MNs appears to be necessary for the rescue of electrophysiological deficits in SMA (139) . Our results therefore show that the prevention of gliosis and MN deafferentation, resulting from activation of Sig1Rs in the absence of SMN expression in MNs, is not sufficient to promote MN survival or improve motor abilities in SMA. However, pharmacological targeting of glial activation and central synaptic loss should not be neglected as a complementary therapy in conjunction with SMN restoration in SMA, particularly in the less severe forms of disease.
